UCB S.A. - Product Pipeline Review - 2015

1 of 3
UCB S.A. - Product Pipeline Review - 2015

Summary

This, ‘UCB S.A. - Product Pipeline Review - 2015’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of UCB S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the UCB S.A.’s pipeline products

Reasons to buy

- Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of UCB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the UCB S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures
UCB S.A. Snapshot
UCB S.A. Overview
Key Information
Key Facts
UCB S.A. - Research and Development Overview
Key Therapeutic Areas
UCB S.A. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
UCB S.A. - Pipeline Products Glance
UCB S.A. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
UCB S.A. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
UCB S.A. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
UCB S.A. - Drug Profiles
brivaracetam
Product Description
Mechanism of Action
R&D Progress
certolizumab pegol
Product Description
Mechanism of Action
R&D Progress
levetiracetam
Product Description
Mechanism of Action
R&D Progress
epratuzumab
Product Description
Mechanism of Action
R&D Progress
lacosamide
Product Description
Mechanism of Action
R&D Progress
rotigotine
Product Description
Mechanism of Action
R&D Progress
bimekizumab
Product Description
Mechanism of Action
R&D Progress
dapirolizumab pegol
Product Description
Mechanism of Action
R&D Progress
UCB-0942
Product Description
Mechanism of Action
R&D Progress
UCB-5857
Product Description
Mechanism of Action
R&D Progress
UCB-7665
Product Description
Mechanism of Action
R&D Progress
Antibodies for Cancer, Immunology and Inflammation
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease
Product Description
Mechanism of Action
R&D Progress
VR-942
Product Description
Mechanism of Action
R&D Progress
Antibodies for Diabetes and Metabolic Disorders
Product Description
Mechanism of Action
R&D Progress
Antibody to Inhibit Transglutaminase 2 for Fibrosis
Product Description
Mechanism of Action
R&D Progress
UCB S.A. - Pipeline Analysis
UCB S.A. - Pipeline Products by Target
UCB S.A. - Pipeline Products by Route of Administration
UCB S.A. - Pipeline Products by Molecule Type
UCB S.A. - Pipeline Products by Mechanism of Action
UCB S.A. - Recent Pipeline Updates
UCB S.A. - Dormant Projects
UCB S.A. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CDP-323
CDP-435
CDP-484
CDP-860
lacosamide
seletracetam
UCB-2892
WX-037
WX-554
UCB S.A. - Company Statement
UCB S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
UCB S.A., Key Information
UCB S.A., Key Facts
UCB S.A. - Pipeline by Indication, 2015
UCB S.A. - Pipeline by Stage of Development, 2015
UCB S.A. - Monotherapy Products in Pipeline, 2015
UCB S.A. - Partnered Products in Pipeline, 2015
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015
UCB S.A. - Out-Licensed Products in Pipeline, 2015
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015
UCB S.A. - Pre-Registration, 2015
UCB S.A. - Phase III, 2015
UCB S.A. - Phase II, 2015
UCB S.A. - Phase I, 2015
UCB S.A. - Preclinical, 2015
UCB S.A. - Discovery, 2015
UCB S.A. - Pipeline by Target, 2015
UCB S.A. - Pipeline by Route of Administration, 2015
UCB S.A. - Pipeline by Molecule Type, 2015
UCB S.A. - Pipeline Products by Mechanism of Action, 2015
UCB S.A. - Recent Pipeline Updates, 2015
UCB S.A. - Dormant Developmental Projects,2015
UCB S.A. - Discontinued Pipeline Products, 2015
UCB S.A., Subsidiaries

List of Figures
UCB S.A. - Pipeline by Top 10 Indication, 2015
UCB S.A. - Pipeline by Stage of Development, 2015
UCB S.A. - Monotherapy Products in Pipeline, 2015
UCB S.A. - Partnered Products in Pipeline, 2015
UCB S.A. - Out-Licensed Products in Pipeline, 2015
UCB S.A. - Pipeline by Top 10 Target, 2015
UCB S.A. - Pipeline by Top 10 Route of Administration, 2015
UCB S.A. - Pipeline by Top 10 Molecule Type, 2015
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll